title: Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.
abstract: A common feature of the neuropsychiatric disorders for which antipsychotic drugs are prescribed is cognitive dysfunction, yet the effects of long-term antipsychotic treatment on cognition are largely unknown. In the current study, we evaluated the effects of long-term oral treatment with the first-generation antipsychotic haloperidol (1.0 and 2.0 mg/kg daily) and the second-generation antipsychotic risperidone (1.25 and 2.5 mg/kg daily) on the acquisition and performance of two radial-arm maze (RAM) tasks and a five-choice serial reaction-time task (5C-SRTT) in rats during days 15-60 and 84-320 days of treatment, respectively. In the RAM, neither antipsychotic significantly affected the acquisition or performance of a spatial win shift or a delayed non-match-to-position task. Conversely, in the rats administered 5C-SRTT, haloperidol was associated with profound deficits in performance, and the subjects were not able to progress through all stages of task acquisition. Depending on the dose, risperidone was associated with a greater number of trials to meet specific performance criteria during task acquisition compared with vehicle-treated controls; however, most subjects were eventually able to achieve all levels of task acquisition. Both haloperidol and risperidone also increased the number of perseverative and time-out responses during certain stages of task acquisition, and the response and reward latencies were slightly higher than controls during several stages of the study. These results in rats suggest that while long-term treatment with haloperidol or risperidone may not significantly affect spatial working or short-term memory, both antipsychotics can (depending on dose) impair sustained attention, decrease psychomotor speed, increase compulsive-type behaviors, and impair cognitive flexibility.
authors.affiliation: Department of Pharmacology and Toxicology, Georgia Regents University, Augusta, Georgia (E.J.H., A.V.T.), Department of Biostatistics, Georgia Regents University, Augusta, Georgia (J.L.W.).
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Hutchings
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Waller
authors.forename: Alvin V
authors.initials: AV
authors.lastname: Terry
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects*; D003216:Conditioning, Operant / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects*; D011597:Psychomotor Performance / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000494:pharmacology*; D012691:Serial Learning / Q000187:drug effects; D013028:Space Perception / Q000187:drug effects*; D013995:Time
chemical_list: D014150:Antipsychotic Agents; D006220:Haloperidol; D018967:Risperidone
references.citation: Schizophr Bull. 1994;20(1):31-46
references.pmid: 8197420
references.citation: Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80
references.pmid: 12373437
references.citation: Neuroscience. 2008 Oct 28;156(4):1005-16
references.pmid: 18801413
references.citation: Pediatrics. 2012 Mar;129(3):e771-84
references.pmid: 22351885
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2002 Oct;26(6):1047-54
references.pmid: 12452525
references.citation: J Clin Psychopharmacol. 2004 Apr;24(2):155-60
references.pmid: 15206662
references.citation: Neuropsychopharmacology. 2010 Apr;35(5):1053-62
references.pmid: 20090669
references.citation: Behav Brain Res. 2006 Aug 10;171(2):286-94
references.pmid: 16697060
references.citation: J Pharmacol Exp Ther. 2007 Mar;320(3):961-8
references.pmid: 16966470
references.citation: Neuropsychopharmacology. 2000 Mar;22(3):311-9
references.pmid: 10693159
references.citation: Neuroscience. 2007 Dec 5;150(2):413-24
references.pmid: 17942237
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1079-87
references.pmid: 17015810
references.citation: Int J Neuropsychopharmacol. 2010 Jul;13(6):799-805
references.pmid: 20059802
references.citation: Biol Psychiatry. 2010 Jul 1;68(1):5-16
references.pmid: 20488434
references.citation: J Pharmacol Exp Ther. 1995 Dec;275(3):1090-8
references.pmid: 8531068
references.citation: N Engl J Med. 2005 Sep 22;353(12):1209-23
references.pmid: 16172203
references.citation: Neuroscience. 2007 May 25;146(3):1316-32
references.pmid: 17434684
references.citation: Life Sci. 2006 May 22;78(26):3007-12
references.pmid: 16434058
references.citation: Am J Psychiatry. 2005 May;162(5):1013-6
references.pmid: 15863811
references.citation: Biochem Pharmacol. 2012 Apr 1;83(7):941-51
references.pmid: 22244928
references.citation: Neuropsychopharmacology. 1996 Nov;15(5):429-36
references.pmid: 8914115
references.citation: Psychiatry Clin Neurosci. 2004 Apr;58(2):168-72
references.pmid: 15009822
references.citation: BMJ. 2012 Feb 23;344:e977
references.pmid: 22362541
references.citation: Biol Psychiatry. 2002 Jun 15;51(12):972-8
references.pmid: 12062881
references.citation: Mol Psychiatry. 2005 Jan;10(1):79-104
references.pmid: 15289815
references.citation: Schizophr Bull. 1984;10(2):160-203
references.pmid: 6729409
references.citation: Behav Brain Res. 2003 Dec 17;147(1-2):107-14
references.pmid: 14659576
references.citation: Am J Psychiatry. 2011 Aug;168(8):831-9
references.pmid: 21572163
references.citation: J Consult Psychol. 1956 Oct;20(5):343-50
references.pmid: 13367264
references.citation: Psychopharmacology (Berl). 1991;105(1):93-100
references.pmid: 1745717
references.citation: J Pharmacol Exp Ther. 2006 Aug;318(2):709-24
references.pmid: 16702442
references.citation: Arch Gen Psychiatry. 2006 Nov;63(11):1189-97
references.pmid: 17088499
references.citation: Schizophr Res. 2004 Jun 1;68(2-3):225-33
references.pmid: 15099605
references.citation: Eur J Pharmacol. 2006 Aug 7;542(1-3):108-15
references.pmid: 16806167
references.citation: Expert Rev Neurother. 2010 Jan;10(1):43-57
references.pmid: 20021320
references.citation: J Pharmacol Exp Ther. 2003 May;305(2):625-31
references.pmid: 12606608
references.citation: Eur J Pharmacol. 2004 Feb 20;486(2):175-82
references.pmid: 14975706